Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab

PURPOSE: Biomarkers for outcome after immune-checkpoint blockade are strongly needed as these may influence individual treatment selection or sequence. We aimed to identify baseline factors associated with overall survival (OS) following pembrolizumab treatment in melanoma patients. EXPERIMENTAL DES...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Weide, Benjamin, Martens, Alexander, Hassel, Jessica C., Berking, Carola, Postow, Michael A., Bisschop, Kees, Simeone, Ester, Mangana, Johanna, Schilling, Bastian, Di Giacomo, Anna Maria, Brenner, Nicole, Kähler, Katharina, Heinzerling, Lucie, Gutzmer, Ralf, Bender, Armin, Gebhardt, Christoffer, Romano, Emanuela, Meier, Friedegund, Martus, Peter, Maio, Michele, Blank, Christian, Schadendorf, Dirk, Dummer, Reinhard, Ascierto, Paolo A., Hospers, Geke, Garbe, Claus, Wolchok, Jedd D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5572569/
https://ncbi.nlm.nih.gov/pubmed/27185375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0127
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados